Our Blog

Air pollution and increased dementia risk

  Recent research led by the University of Washington showed that air pollution can increase the risk of dementia by up to 16%. In addition, the UN Report […]

Brain Fog and Long Covid

Brain Fog and Long Covid Dr Steve Allder, Consultant Neurologist at Re:Cognition Health:   It is unknown who is most affected by cognitive complaints induced by Covid-19 […]

Long Covid Metro blog

Long Covid Metro blog   Brain Fog & Long Covid Consultant Neurologist Dr Steve Allder shares his insight with the Metro:   Dr Steve Allder was recently […]

Turning Point for Brain Injury in Contact Sport

  Re:Cognition Health is delighted to read the  recommendations and insights published on 22 July 2021 by  the  Department for Digital, Media, Culture and Sport, the Drake […]

Biogen FDA Accelerated Approval Under Investigation

  By Rigby Sampson On Friday 9th July, Janet Woodcock the Acting Commissioner of the FDA (and former Director of the Centre for Drug Evaluation and Research […]

Minimum

  Pollution and the brain   Re:Cognition Health applaud new Fintech start up Minimum.eco dedicated to making carbon neutrality easily accessible to all businesses. Minimum enables businesses to calculate and offset the carbon footprint of its […]

Proactive Measures To Protect Against Dementia

Dr Emer MacSweeney was featured in the Daily Mail, exploring some of the proactive measures we can take to help protect against dementia. At Re:Cognition Health, we […]

The negative effects of working long hours

The negative effects of working long hours   According to a recent global study, 745,000 people died in the past 12 months, from heart disease or stroke […]

IS ADHD Over-Diagnosed in Children and Adolescents?

IS ADHD Over-Diagnosed in Children and Adolescents?   A recent study published in JAMA (Journal of the American Medical Association)  Network has revealed that Attention Deficit Hyperactivity […]

Aducanumab, what this means for the UK

Aducanumab, what this means for the UK        On Monday 7th June 2021 the USA approved the first medication, ever, to combat the underlying cause of Alzheimer’s Disease. Aducanumab, […]